K C Anderson

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications
    D Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Apoptosis 8:337-43. 2003
  2. doi request reprint Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
    N Raje
    Division of Hematologic Malignancies, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02114, USA
    Leukemia 23:961-70. 2009
  3. ncbi request reprint The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications
    T Hideshima
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, MA 02115, USA
    Oncogene 20:4519-27. 2001
  4. ncbi request reprint Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
    D Gupta
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 15:1950-61. 2001
  5. ncbi request reprint The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    T Hideshima
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 61:3071-6. 2001
  6. ncbi request reprint TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
    C S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 98:795-804. 2001
  7. ncbi request reprint Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
    K Podar
    Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Blood 98:428-35. 2001
  8. ncbi request reprint Novel therapies targeting the myeloma cell and its bone marrow microenvironment
    T Hideshima
    Department of Adult Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 28:607-12. 2001
  9. ncbi request reprint High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission
    A S Freedman
    Division of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 16:13-8. 1998
  10. doi request reprint Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    I Breitkreutz
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 22:1925-32. 2008

Collaborators

Detail Information

Publications73

  1. ncbi request reprint Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications
    D Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Apoptosis 8:337-43. 2003
    ....
  2. doi request reprint Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
    N Raje
    Division of Hematologic Malignancies, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02114, USA
    Leukemia 23:961-70. 2009
    ..Finally, in vivo efficacy of P276-00 was confirmed in an MM xenograft model. These studies form the basis of an ongoing phase I study in the treatment of relapsed/refractory MM...
  3. ncbi request reprint The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications
    T Hideshima
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, MA 02115, USA
    Oncogene 20:4519-27. 2001
    ..Agents which act to inhibit TNFalpha may therefore abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment...
  4. ncbi request reprint Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
    D Gupta
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 15:1950-61. 2001
    ..These data demonstrate the importance of stromal-MM cell interactions in regulating VEGF and IL-6 secretion, and suggest additional mechanisms whereby thalidomide and IMiD1-CC4047 act against MM cells in the BM millieu...
  5. ncbi request reprint The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    T Hideshima
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 61:3071-6. 2001
    ..Given the acceptable animal and human toxicity profile of PS-341, these studies provide the framework for clinical evaluation of PS-341 to improve outcome for patients with this universally fatal hematological malignancy...
  6. ncbi request reprint TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
    C S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 98:795-804. 2001
    ..These preclinical studies suggest that TRAIL/Apo2L can overcome conventional drug resistance and provide the basis for clinical trials of TRAIL-based treatment regimens to improve outcome in patients with MM. (Blood. 2001;98:795-804)..
  7. ncbi request reprint Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
    K Podar
    Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Blood 98:428-35. 2001
    ..These observations provide the framework for novel therapeutic strategies targeting VEGF signaling cascades in MM...
  8. ncbi request reprint Novel therapies targeting the myeloma cell and its bone marrow microenvironment
    T Hideshima
    Department of Adult Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 28:607-12. 2001
    ..These data indicate that VEGF plays a pivotal role not only in neoangiogenesis in MM BM but also in proliferation and migration of tumor cells...
  9. ncbi request reprint High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission
    A S Freedman
    Division of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 16:13-8. 1998
    ....
  10. doi request reprint Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    I Breitkreutz
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 22:1925-32. 2008
    ..We conclude that both agents specifically target key factors in osteoclastogenesis, and could directly affect the MM-OCL-BMSCs activation loop in osteolytic bone disease...
  11. pmc AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition
    L Santo
    Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 29:2325-36. 2010
    ..These results offer new insights into the crucial, yet controversial role of GSK-3beta in MM and show significant anti-MM activity of AT7519, providing the rationale for its clinical evaluation in MM...
  12. ncbi request reprint Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    F E Davies
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 98:210-6. 2001
    ..Thus in vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function...
  13. ncbi request reprint Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
    S P Treon
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston Massachusetts 02115, USA
    J Immunother 24:263-71. 2001
    ..A prospective, clinical study is assessing the role of these antigens in mediating rituximab resistance...
  14. ncbi request reprint A pivotal role for Mcl-1 in Bortezomib-induced apoptosis
    K Podar
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 022115, USA
    Oncogene 27:721-31. 2008
    ..To prevent relapse of MM in patients treated with Bortezomib, we therefore recommend the combination of Bortezomib with agents that induce MM cell death independent of Mcl-1...
  15. ncbi request reprint Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage
    Y T Tai
    Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 165:6347-55. 2000
    ..Coupled with a recent report that Ku86 activity correlates with resistance to radiation and chemotherapy, these results have implications for the potential role of Ku86 as a novel therapeutic target...
  16. doi request reprint A novel role for CCL3 (MIP-1╬▒) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
    S Vallet
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Leukemia 25:1174-81. 2011
    ..Our results show that CCL3, in addition to its known catabolic activity, reduces bone formation by inhibiting OB function, and therefore contributes to OB/OC uncoupling in MM...
  17. ncbi request reprint A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
    D Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 26:2374-80. 2007
    ....
  18. ncbi request reprint Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
    P Neri
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 21:2519-26. 2007
    ..Taken together, these data demonstrate the in vitro and in vivo antitumor activity of Atip, delineate potential molecular targets triggered by this agent, and provide a preclinical rational for its clinical evaluation in MM...
  19. ncbi request reprint Isolation and characterization of human multiple myeloma cell enriched populations
    Y T Tai
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Immunol Methods 235:11-9. 2000
    ..This immunomagnetic bead depletion method therefore permits the ready isolation of homogeneous populations of patient MM cells for use in both cellular and molecular studies...
  20. ncbi request reprint Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
    T Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 20:5991-6000. 2001
    ..Our data therefore suggest that PI3-K/Akt signaling mediates growth, survival, and cell cycle regulatory effects of IL-6 in MM...
  21. ncbi request reprint Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway
    H Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Leukemia 21:535-40. 2007
    ..Importantly, growth of MM cells adherent to bone marrow (BM) stromal cells is also significantly inhibited by SDX-308. Our data therefore indicate that the novel etodolac analog SDX-308 can target MM cells in the BM milieu...
  22. ncbi request reprint Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias
    N Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Expert Opin Investig Drugs 10:1521-30. 2001
    ..These studies provide a framework for the use of TRAIL/Apo2L as a single agent or as part of combination therapy for the treatment of MM...
  23. doi request reprint Ascorbic acid inhibits antitumor activity of bortezomib in vivo
    G Perrone
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 23:1679-86. 2009
    ....
  24. ncbi request reprint Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells
    N Raje
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02114, USA
    Br J Haematol 135:52-61. 2006
    ..7 as determined by the Chou-Talalay method. These studies therefore provide the preclinical rationale for evaluation of Didox, alone and in combination with DNA-damaging agents, to improve patient outcome in MM...
  25. pmc The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    J P Laubach
    Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA
    Leukemia 23:2222-32. 2009
    ..This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease...
  26. ncbi request reprint Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
    E P Alyea
    Divisions of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 91:3671-80. 1998
    ....
  27. ncbi request reprint Novel biologically based therapies for myeloma
    K C Anderson
    Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer J 7:S19-23. 2001
    ..Adenoviral purging prior to autotransplantation and in vivo and ex vivo stimulation of autoimmune cells are discussed as potential approaches to address these problems...
  28. ncbi request reprint Management of treatment-emergent peripheral neuropathy in multiple myeloma
    P G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 26:595-608. 2012
    ..Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions...
  29. ncbi request reprint Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells
    D Chauhan
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Biol Chem 276:24453-6. 2001
    ..Taken together, these findings demonstrate that Smac plays a functional role in mediating Dex-induced caspase-9 activation and apoptosis in MM cells...
  30. pmc Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
    D Cirstea
    1 MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 2 Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Boston, MA, USA
    Leukemia 27:2366-75. 2013
    ....
  31. ncbi request reprint Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies
    K Podar
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Curr Cancer Drug Targets 11:1005-24. 2011
    ....
  32. ncbi request reprint Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
    S P Treon
    Dana Farber Cancer Institute, Boston, MA, USA
    Ann Oncol 11:107-11. 2000
    ..In addition to Muc-1 core protein, we have also been examining the use of CD20 directed serotherapy for PCD...
  33. ncbi request reprint Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies
    M B Vidriales
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Mol Med Today 2:425-31. 1996
    ..It might therefore be possible to develop innovative treatment strategies either to inhibit interleukin 6 production or to interrupt interleukin 6 signal transduction in multiple myeloma...
  34. ncbi request reprint Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling
    O Tournilhac
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 17:1275-82. 2006
    ..These studies demonstrate that in WM, MC may support tumor cell expansion through constitutive CD154-CD40 signaling and therefore provide the framework for therapeutic targeting of MC and MC-WM cell interactions in WM...
  35. pmc Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma
    J Bae
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 25:1610-9. 2011
    ....
  36. pmc HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
    W Song
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 25:161-8. 2011
    ..It also provides a rationale to evaluate LBH589 activity for the treatment of inflammation...
  37. doi request reprint Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
    J Minami
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Leukemia 28:680-9. 2014
    ..Our results indicate that HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM. ..
  38. ncbi request reprint 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27
    D Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Apoptosis 9:149-55. 2004
    ..Finally, blockade of Hsp27 by anti-sense strategy enhanced anti-MM activity of both 2ME2 and PS-341. These findings provide the clinical application of novel therapeutics targeting Hsp27 to improve patient outcome in MM...
  39. ncbi request reprint Extended rituximab therapy in Waldenstr├Âm's macroglobulinemia
    S P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Ann Oncol 16:132-8. 2005
    ..Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m(2)/week...
  40. pmc Bone marrow microenvironment and the identification of new targets for myeloma therapy
    K Podar
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 23:10-24. 2009
    ..Ongoing studies are further delineating MM pathogenesis in the BM to enhance cytotoxicity, avoid drug resistance and improve patient outcome...
  41. ncbi request reprint CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
    S P Treon
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Immunother 24:272-9. 2001
    ..A prospective clinical trial to more completely define the benefit of single-agent rituximab in patients with WM has been initiated by many of our centers...
  42. ncbi request reprint Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
    S Kumar
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, VA Boston Healthcare System and Harvard Medical School, Boston, MA 02115, USA
    Leukemia 19:1253-61. 2005
    ..They have potent antiangiogenic activity and direct effect on bone marrow stroma. These encouraging preclinical data provide the basis for further evaluation in the clinic...
  43. ncbi request reprint Adenovirus vector-based purging of multiple myeloma cells
    G Teoh
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA and the Department of Haematology, Singapore General Hospital, Singapore
    Blood 92:4591-601. 1998
    ..These findings demonstrate that transduction with Ad vectors using a tumor-selective promoter provides a highly efficient and selective approach for the ex vivo purging of MM cells...
  44. pmc A novel proteasome inhibitor NPI-0052 as an anticancer therapy
    D Chauhan
    Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, The Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA
    Br J Cancer 95:961-5. 2006
    ..These preclinical studies provided the basis for Phase-I clinical trial of NPI-0052 in relapsed/refractory MM patients...
  45. ncbi request reprint Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug
    N Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Mayer Building, 44 Biney Street, Boston MA 02115, USA
    Expert Opin Investig Drugs 10:1075-84. 2001
    ....
  46. ncbi request reprint A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 113:455-60. 2001
    ....
  47. ncbi request reprint Targeted treatments to improve stem cell outcome: old and new drugs
    M S Raab
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Bone Marrow Transplant 40:1129-37. 2007
    ..Bone Marrow Transplantation (2007) 40, 1129-1137; doi:10.1038/sj.bmt.1705829; published online 3 September 2007...
  48. pmc A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice
    Y Hu
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood Cancer J 3:e156. 2013
    ....
  49. ncbi request reprint Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
    S Jagannath
    Department of Medical Oncology, St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Leukemia 21:151-7. 2007
    ..These matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del(13) as an independent prognostic factor. However, sample sizes were very small; these findings require confirmation from further studies...
  50. ncbi request reprint Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma
    S Lentzsch
    Enders 1006, Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA
    Semin Oncol 28:597-601. 2001
    ..The effects of an inhibitor of both the tumor and vascular compartments of a tumor on tumor growth may be synergistic...
  51. ncbi request reprint Targeted therapy for multiple myeloma
    K C Anderson
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Semin Hematol 38:286-94. 2001
    ..These therapies, alone or in combination with conventional treatments, offer great promise to improve the outcome for patients with MM...
  52. ncbi request reprint Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
    E Alyea
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, MA 02215, USA
    Bone Marrow Transplant 32:1145-51. 2003
    ..Strategies focused on reducing nonrelapse mortality in allogeneic transplantation may translate into an improved outcome for patients receiving allogeneic transplantation...
  53. ncbi request reprint Apoptosis in multiple myeloma: therapeutic implications
    D Chauhan
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Apoptosis 6:47-55. 2001
    ..The current review focuses on the studies of apoptotic and survival signaling pathways in MM cells, which have both identified novel apoptotic and anti-apoptotic proteins and provided targets for novel therapeutics...
  54. ncbi request reprint Multiple Myeloma. Advances in disease biology: therapeutic implications
    K C Anderson
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Semin Hematol 38:6-10. 2001
    ..Immune-based therapies will likely play an increasing role in the treatment of multiple myeloma, and novel approaches are directed to generating immune responses to specific multiple myeloma antigens...
  55. ncbi request reprint CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
    R J Soiffer
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1152-9. 2001
    ..Herein, we report results in the first 48 recipients of unrelated marrow using CD6+ TCD as the sole form of GVHD prophylaxis...
  56. pmc CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
    Y T Tai
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Leukemia 28:155-65. 2014
    ..These results support clinical development of SINE CRM1 antagonists to improve patient outcome in MM. ..
  57. ncbi request reprint Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
    S Lentzsch
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Leukemia 17:41-4. 2003
    ..Our results therefore show that the IMiDs have more potent direct anti-tumor and anti-angiogenic effects than thalidomide in vivo, providing the framework for clinical protocols evaluating these agents in MM and other B cell neoplasms...
  58. ncbi request reprint Clinically relevant end points and new drug approvals for myeloma
    K C Anderson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 22:231-9. 2008
    ..This manuscript will therefore be a most valuable resource to provide the framework for the design of appropriate clinical trial strategies for more rapid new drug approval in myeloma...
  59. pmc Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients
    B Maecker
    Department of Adult Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Clin Exp Immunol 141:558-62. 2005
    ..These results suggest that strategies targeting hTERT and CYP1B1 may have to utilize techniques to induce T cell responses from a naive precursor frequency...
  60. ncbi request reprint Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice
    D A Dedera
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 94:53-61. 1996
    ..These data demonstrate that IL-6 is required for pristane-induced hyperplasia of polyclonal plasma cells in mice...
  61. ncbi request reprint Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia
    S P Treon
    Waldenstrom s Macroglobulinemia Program, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02116, USA
    Ann Oncol 15:1481-3. 2004
    ..Paradoxically, we have observed that serum IgM levels can abruptly rise following rituximab therapy in patients with WM, and can often lead to morbidity on the basis of hyperviscosity...
  62. ncbi request reprint SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
    D Chauhan
    Department of Adult Oncology, Dana Farber Cancer Institute, Division of Experimental Medicine and Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 275:27845-50. 2000
    ..These findings demonstrate that SHP2 mediates the anti-apoptotic effect of IL-6 and suggest SHP2 as a novel therapeutic target in MM...
  63. pmc Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells
    D Chauhan
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Exp Med 182:1801-6. 1995
    ..The SH2 domain of Grb2 is directly associated with tyrosine-phosphorylated JAK2. Furthermore, the presence of Sos in the JAK2-Grb2 complex suggests a role for Ras in OSM-transduced signaling...
  64. pmc Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
    M A Shammas
    Department of Medicine, VA Boston Healthcare System, MA, USA
    Leukemia 22:1410-8. 2008
    ..Furthermore, GRN163L-induced myeloma cell death could be significantly enhanced by Hsp90 inhibitor 17AAG. These data provide the preclinical rationale for clinical evaluation of GRN163L in myeloma and in combination with 17AAG...
  65. ncbi request reprint Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
    T A Navas
    Scios, Inc, Fremont, CA, USA
    Leukemia 20:1017-27. 2006
    ....
  66. ncbi request reprint Bortezomib as an antitumor agent
    A M Roccaro
    Department of 1Internal Medicine and Oncology, University of Bari MedicalSchool, Bari, Italy
    Curr Pharm Biotechnol 7:441-8. 2006
    ..Its anti-tumor activities earlier in the course, in combination therapies, and in other malignancies is ongoing...
  67. ncbi request reprint A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
    S Jagannath
    St Vincent s Catholic Medical Center, New York, NY, USA
    Br J Haematol 127:165-72. 2004
    ..Grade 4 events were observed in 9% (five of 54 patients). Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy...
  68. ncbi request reprint Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
    A Palumbo
    Division of Hematology, University of Turin, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Leukemia 22:414-23. 2008
    ..Further investigation is needed to define the best VTE prophylaxis...
  69. doi request reprint Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
    J F San-Miguel
    Department of Hematology, Hospital Universitario CIC Universidad de Salamanca CSIC, Salamanca, Spain
    Leukemia 22:842-9. 2008
    ..These results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency. Efficacy/safety were not substantially affected by severe-to-moderate vs no/mild impairment...
  70. ncbi request reprint The evolving background for high-dose treatment for myeloma
    B Sirohi
    Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK
    Bone Marrow Transplant 40:1097-100. 2007
    ....
  71. ncbi request reprint Immunotherapy for multiple myeloma: insights from other models
    F K Stevenson
    Tenovus Research Laboratory, Department of Molecular Immunology, Southampton General Hospital, UK
    Leuk Res 26:403-5. 2002
  72. pmc Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution
    A K Stewart
    Leukemia 21:2358-9. 2007
  73. ncbi request reprint B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes
    L M Nadler
    J Immunol 131:244-50. 1983
    ..Moreover, the observation that B4 is expressed on almost all early B cell tumors suggests that it may precede B1, CALLA, cytoplasmic mu, and B2 in early B cell ontogeny...